Thermo Fisher Scientific (TMO) Stake Lowered by AMF Pensionsforsakring AB

AMF Pensionsforsakring AB decreased its position in Thermo Fisher Scientific (NYSE:TMO) by 23.4% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 357,025 shares of the medical research company’s stock after selling 109,366 shares during the quarter. AMF Pensionsforsakring AB owned approximately 0.09% of Thermo Fisher Scientific worth $73,711,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in TMO. Viking Global Investors LP acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $154,660,000. BlackRock Inc. grew its stake in shares of Thermo Fisher Scientific by 2.0% in the first quarter. BlackRock Inc. now owns 24,582,453 shares of the medical research company’s stock worth $5,075,294,000 after acquiring an additional 475,267 shares during the last quarter. Longview Partners Guernsey LTD grew its stake in shares of Thermo Fisher Scientific by 6.8% in the fourth quarter. Longview Partners Guernsey LTD now owns 4,876,890 shares of the medical research company’s stock worth $926,024,000 after acquiring an additional 311,977 shares during the last quarter. Elkfork Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the fourth quarter worth $46,978,000. Finally, Schroder Investment Management Group grew its stake in shares of Thermo Fisher Scientific by 28.1% in the fourth quarter. Schroder Investment Management Group now owns 1,103,685 shares of the medical research company’s stock worth $209,568,000 after acquiring an additional 242,062 shares during the last quarter. 85.86% of the stock is currently owned by institutional investors.

In other news, CEO Marc N. Casper sold 40,000 shares of the business’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $210.16, for a total value of $8,406,400.00. Following the sale, the chief executive officer now owns 334,622 shares in the company, valued at approximately $70,324,159.52. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, March 5th. The shares were sold at an average price of $204.60, for a total transaction of $511,500.00. The disclosure for this sale can be found here. Insiders sold a total of 42,706 shares of company stock worth $8,962,073 in the last 90 days. 0.49% of the stock is owned by corporate insiders.

TMO opened at $213.65 on Friday. Thermo Fisher Scientific has a fifty-two week low of $170.07 and a fifty-two week high of $226.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.95 and a current ratio of 1.36. The firm has a market cap of $87.11 billion, a price-to-earnings ratio of 22.51, a price-to-earnings-growth ratio of 1.59 and a beta of 1.14.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.42 by $0.08. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. The company had revenue of $5.85 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the company earned $2.08 EPS. The firm’s revenue for the quarter was up 22.8% compared to the same quarter last year. sell-side analysts anticipate that Thermo Fisher Scientific will post 10.9 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Monday, July 16th. Stockholders of record on Friday, June 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $0.68 annualized dividend and a dividend yield of 0.32%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, March 26th. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $223.00 to $227.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. Barclays lifted their price target on shares of Thermo Fisher Scientific from $225.00 to $245.00 and gave the stock an “overweight” rating in a research note on Thursday, February 1st. ValuEngine upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Friday, February 2nd. Finally, Bank of America lifted their price target on shares of Thermo Fisher Scientific from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, February 1st. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $224.38.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific (NYSE:TMO).

Institutional Ownership by Quarter for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply